

Erratum to: Acyclovir resistance in herpes simplex virus type I encephalitis: a case report

M. Bergmann¹ · R. Beer¹ · M. Kofler¹ · R. Helbok¹ · B. Pfausler¹ · E. Schmutzhard¹

Published online: 29 June 2017
© Journal of NeuroVirology, Inc. 2017

Erratum to: J. Neurovirol. (2017) 23:335–337
DOI 10.1007/s13365-016-0489-5

We apologize for the mistake which slipped through all careful reading and re-reading: it must, correctly, read throughout the entire paper ... foscarnet i.v. 60 mg **per kg bodyweight (b.w.)**, t.i.d.

It is correct that 40 mg/kg b.w. is the recommended daily dose (Chilukuri and Rosen 2011), but in view of the dramatic clinical and neuro-imaging course we opted for an increased dose carefully monitoring for side effects.

References

- Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E (2017) Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. *J Neurovirol* 23(2):335–337
- Chilukuri S, Rosen T (2003) Management of acyclovir-resistant herpes simplex virus. *Dermatol Clin* 21:311–320

The online version of the original article can be found at <http://dx.doi.org/10.1007/s13365-016-0489-5>

✉ E. Schmutzhard
erich.schmutzhard@i-med.ac.at

¹ Department of Neurology, Neurocritical Care Unit, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria